Roche's Eylea rival poised for FDA filings with new phase 3 data

Retrieved on: 2021-02-12 14:03:45

Tags for this article:

Click the tags to see associated articles and topics

Roche's Eylea rival poised for FDA filings with new phase 3 data. View article details on hiswai:

Excerpt

Roche's bispecific antibody matched Regeneron's blockbuster Eylea in four phase 3 studies comparing the two in diabetic macular edema (DME) and ...

Article found on: www.fiercebiotech.com